Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.76
NAS:AGEN's Cash to Debt is ranked lower than
82% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. NAS:AGEN: 0.76 )
Ranked among companies with meaningful Cash to Debt only.
NAS:AGEN' s Cash to Debt Range Over the Past 10 Years
Min: 0.24  Med: 1.48 Max: N/A
Current: 0.76
Equity to Asset -0.12
NAS:AGEN's Equity to Asset is ranked lower than
94% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AGEN: -0.12 )
Ranked among companies with meaningful Equity to Asset only.
NAS:AGEN' s Equity to Asset Range Over the Past 10 Years
Min: -1.33  Med: 0.07 Max: 0.92
Current: -0.12
-1.33
0.92
F-Score: 3
Z-Score: -7.68
M-Score: -2.71
WACC vs ROIC
20.42%
-1248.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -430.05
NAS:AGEN's Operating margin (%) is ranked lower than
68% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. NAS:AGEN: -430.05 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:AGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -7314.02  Med: -669.99 Max: -42.23
Current: -430.05
-7314.02
-42.23
Net-margin (%) -472.80
NAS:AGEN's Net-margin (%) is ranked lower than
70% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:AGEN: -472.80 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:AGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -7497.25  Med: -753.65 Max: -70.95
Current: -472.8
-7497.25
-70.95
ROE (%) -310.34
NAS:AGEN's ROE (%) is ranked lower than
95% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. NAS:AGEN: -310.34 )
Ranked among companies with meaningful ROE (%) only.
NAS:AGEN' s ROE (%) Range Over the Past 10 Years
Min: -726.2  Med: -460.59 Max: -187.92
Current: -310.34
-726.2
-187.92
ROA (%) -54.06
NAS:AGEN's ROA (%) is ranked lower than
69% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. NAS:AGEN: -54.06 )
Ranked among companies with meaningful ROA (%) only.
NAS:AGEN' s ROA (%) Range Over the Past 10 Years
Min: -94.08  Med: -59.91 Max: -46.32
Current: -54.06
-94.08
-46.32
ROC (Joel Greenblatt) (%) -650.29
NAS:AGEN's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:AGEN: -650.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:AGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -986.59  Med: -280.29 Max: -196.65
Current: -650.29
-986.59
-196.65
Revenue Growth (3Y)(%) -22.30
NAS:AGEN's Revenue Growth (3Y)(%) is ranked lower than
76% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:AGEN: -22.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:AGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.9  Med: -10.55 Max: 96.1
Current: -22.3
-53.9
96.1
EBITDA Growth (3Y)(%) 68.10
NAS:AGEN's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:AGEN: 68.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:AGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.9  Med: -15.7 Max: 68.1
Current: 68.1
-50.9
68.1
EPS Growth (3Y)(%) 30.10
NAS:AGEN's EPS Growth (3Y)(%) is ranked higher than
83% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:AGEN: 30.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:AGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.7  Med: -16.05 Max: 30.1
Current: 30.1
-39.7
30.1
GuruFocus has detected 4 Warning Signs with Agenus Inc $NAS:AGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AGEN's 10-Y Financials

Financials (Next Earnings Date: 2017-03-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AGEN Guru Trades in Q1 2016

Robert Bruce 233,515 sh (unchged)
Ken Fisher 91,632 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 1,140,315 sh (-5.30%)
Steven Cohen 1,536,948 sh (-60.14%)
» More
Q2 2016

AGEN Guru Trades in Q2 2016

Ken Fisher 93,132 sh (+1.64%)
Robert Bruce 233,515 sh (unchged)
Steven Cohen Sold Out
Jim Simons 517,017 sh (-54.66%)
» More
Q3 2016

AGEN Guru Trades in Q3 2016

Jim Simons Sold Out
Ken Fisher 62,549 sh (-32.84%)
Robert Bruce 155,677 sh (-33.33%)
» More
Q4 2016

AGEN Guru Trades in Q4 2016

Ken Fisher 62,549 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:PRTK, NAS:NLNK, NAS:ADXS, NAS:RARX, NAS:BOLD, NAS:ARNA, NAS:SVA, NAS:ADAP, NAS:EDGE, NAS:BLCM, NAS:GERN, AMEX:BTX, NAS:CARA, NAS:CLDX, NAS:TRVN, NAS:NOVN, NAS:CRBP, NAS:MNKD, OTCPK:MDGEF, NAS:PTGX » details
Traded in other countries:AJ81.Germany,
Agenus Inc along with its subsidiaries is a biopharmaceutical company. The Company is engaged in developing and commercializing technologies to treat cancers and degenerative disorders.

Agenus Inc formerly known as Antigenics Inc was incorporated in 1994. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform. Within HSP Platform the Company is developing its Prophage Series cancer vaccines and Recombinant Series. In Prophage Series the Company has tested product candidates in Phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for metastatic melanoma, as well as in Phase 1 and Phase 2 clinical trials. In addition, the Cancer Therapy Evaluation Program of the National Cancer Institute opened patient enrollment in 2013 for a 222-patient, multi-center, randomized Phase 2 trial of Prophage Series vaccine G-200 in combination with Avastin in patients with surgically resectable recurrent glioma. HerpV, a therapeutic vaccine candidate from the Recombinant Series which contains QS-21 Stimulon, has been tested in a Phase 1 clinical trial for the treatment of genital herpes and is now in a Phase 2 trial. Within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis. The Company's business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of its collaborations. The Company faces intense competition from pharmaceutical companies and specialized biotechnology companies that market products or that are engaged in the development of product candidates directed at cancer, infectious diseases and degenerative disorders. Several of these companies have products that utilize similar technologies and patient-specific medicine techniques. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act and the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.

Top Ranked Articles about Agenus Inc

Weekly CEO Buys Highlights Agenus, JCPenney, Intrepid Potash, Opko Health, Seneca top list
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/S 12.89
AGEN's P/S is ranked lower than
55% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. AGEN: 12.89 )
Ranked among companies with meaningful P/S only.
AGEN' s P/S Range Over the Past 10 Years
Min: 4.59  Med: 25.59 Max: 517.6
Current: 12.89
4.59
517.6
Current Ratio 3.14
AGEN's Current Ratio is ranked lower than
61% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AGEN: 3.14 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.77 Max: 42.49
Current: 3.14
0.64
42.49
Quick Ratio 3.14
AGEN's Quick Ratio is ranked lower than
58% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AGEN: 3.14 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.73 Max: 42.49
Current: 3.14
0.64
42.49
Days Sales Outstanding 152.36
AGEN's Days Sales Outstanding is ranked lower than
85% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. AGEN: 152.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.12  Med: 20.97 Max: 152.36
Current: 152.36
0.12
152.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -52.00
AGEN's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. AGEN: -52.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -20.1 Max: -1.5
Current: -52
-52
-1.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.50
AGEN's Price/Median PS Value is ranked higher than
80% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. AGEN: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
AGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.21 Max: 138.86
Current: 0.5
0.23
138.86
Earnings Yield (Greenblatt) (%) -30.82
AGEN's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. AGEN: -30.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -61.08  Med: 0 Max: 0
Current: -30.82
-61.08
0

More Statistics

Revenue (TTM) (Mil) $24.64
EPS (TTM) $ -1.35
Beta2.85
Short Percentage of Float13.01%
52-Week Range $2.61 - 7.49
Shares Outstanding (Mil)87.13

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 24 27 28 25
EPS ($) -0.87 -1.19 -1.35 -1.07
EPS w/o NRI ($) -0.87 -1.19 -1.35 -1.07
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Mar 14 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

More From Other Websites
Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo Jan 19 2017
Clinical Trial Hopes Drugs Help Body Fight Cancer Jan 18 2017
Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo Jan 18 2017
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 17 2017
Agenus announces collaboration with the National Cancer Institute to evaluate the combination of... Jan 17 2017
ETFs with exposure to Agenus, Inc. : January 6, 2017 Jan 06 2017
ETFs with exposure to Agenus, Inc. : December 21, 2016 Dec 21 2016
Here is What Hedge Funds Think About Agenus Inc (AGEN) Dec 09 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody... Dec 01 2016
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors Dec 01 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 30 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody... Nov 30 2016
AGENUS INC Financials Nov 17 2016
ETFs with exposure to Agenus, Inc. : November 16, 2016 Nov 16 2016
Agenus to Present at the Jefferies 2016 London Healthcare Conference Nov 14 2016
AGENUS INC Files SEC form 10-Q, Quarterly Report Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)